

February 9, 2021

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

Ref: Scrip Code: 532296

Dear Sirs,

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Name: GLENMARK

Re: Intimation of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 to consider repurchase of Foreign Currency Debt

- A. We hereby inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, a meeting of the Board of Directors of Glenmark Pharmaceuticals Limited ("Company") will be held on February 12, 2021, to consider opportunistic tenders or buybacks of any part of its Singapore listed foreign currency convertible bonds, being, its U.S.\$200 million (as on date outstanding U.S.\$ 113.5 million) 2 per cent resettable onward starting equity linked securities due June 28, 2022 issued in 2016 ("FCC Bonds"), based on market opportunities and conditions from time to time and to delegate powers to operations committee. The Operations Committee, based on market opportunities and conditions, will hold meetings to consider and approve the terms and conditions of any tenders or buybacks.
- B. This is for the information of your members and all concerned in compliance with the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended.

The above is for your information.

Thanking you

Yours faithfully,

For Glenmark Pharmaceuticals Limited

Harish Ruber

**Company Secretary Compliance Officer** 

Tel: 4018 9999 / 4018 9879

Fax: 4018 9986 (Legal & Secretarial Dept.)